Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Published Study Confirms Safety of InterHealth’s Super CitriMax®
Results of a study published in the June issue of Toxicology Mechanisms and Methods, further affirms the long-term safety of Super CitriMax®.
- Published Study Confirms Safety of InterHealth’s Super CitriMax®
Results of a study published in the June issue of Toxicology Mechanisms and Methods, further affirms the long-term safety of Super CitriMax®.
- Clinical Trial on Hospitalized Children Suffering from Lead Poisoning Reveals the Safety and Effectiveness of Modified Citrus Pectin (MCP)
EcoNugenics announces the results of a collaborative study with the U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS) that reveals the effectiveness and safety of modified citrus pectin (MCP; PectaSol) in dramatically lowering lead toxicity in children who were suffering from severe lead poisoning.
- Clinical Trial on Hospitalized Children Suffering from Lead Poisoning Reveals the Safety and Effectiveness of Modified Citrus Pectin (MCP)
EcoNugenics announces the results of a collaborative study with the U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS) that reveals the effectiveness and safety of modified citrus pectin (MCP; PectaSol) in dramatically lowering lead toxicity in children who were suffering from severe lead poisoning.
- Danone Research announces further progress in the development of its Alzheimer’s product Souvenaid (TM)
Danone Research announces that it has taken an important step forward in the development program for its Alzheimer’s product SouvenaidTM with the successful completion of a first clinical trial.
- Danone Research announces further progress in the development of its Alzheimer’s product Souvenaid (TM)
Danone Research announces that it has taken an important step forward in the development program for its Alzheimer’s product SouvenaidTM with the successful completion of a first clinical trial.
- Danone Research announces further progress in the development of its Alzheimer’s product Souvenaid (TM)
Danone Research announces that it has taken an important step forward in the development program for its Alzheimer’s product SouvenaidTM with the successful completion of a first clinical trial.
- Trace Minerals Research Invites Industry Leaders To Serve On Research Advisory Board
Trace Minerals Research (TMR) has announced the acceptance of Dr. Alexander G. Schauss, Ph.D., FACN, and Dr. Chris D. Meletis, N.D. today to serve as members of its recently established Scientific Research Advisory Board.
- Trace Minerals Research Invites Industry Leaders To Serve On Research Advisory Board
Trace Minerals Research (TMR) has announced the acceptance of Dr. Alexander G. Schauss, Ph.D., FACN, and Dr. Chris D. Meletis, N.D. today to serve as members of its recently established Scientific Research Advisory Board.
- Trace Minerals Research Invites Industry Leaders To Serve On Research Advisory Board
Trace Minerals Research (TMR) has announced the acceptance of Dr. Alexander G. Schauss, Ph.D., FACN, and Dr. Chris D. Meletis, N.D. today to serve as members of its recently established Scientific Research Advisory Board.
- Trace Minerals Research Invites Industry Leaders To Serve On Research Advisory Board
Trace Minerals Research (TMR) has announced the acceptance of Dr. Alexander G. Schauss, Ph.D., FACN, and Dr. Chris D. Meletis, N.D. today to serve as members of its recently established Scientific Research Advisory Board.
- Human Clinical Study Confirms Frutarom’s Neuravena® Enhances Mental Fitness and Stress Resistance
In-vitro and animal trials have demonstrated that Frutarom’s Neuravena® (EFLA® 955) wild green oat extract has a significant, positive effect on brain activity, enhancing mental fitness and stress resistance.
- Human Clinical Study Confirms Frutarom’s Neuravena® Enhances Mental Fitness and Stress Resistance
In-vitro and animal trials have demonstrated that Frutarom’s Neuravena® (EFLA® 955) wild green oat extract has a significant, positive effect on brain activity, enhancing mental fitness and stress resistance.
- Human Clinical Study Confirms Frutarom’s Neuravena® Enhances Mental Fitness and Stress Resistance
In-vitro and animal trials have demonstrated that Frutarom’s Neuravena® (EFLA® 955) wild green oat extract has a significant, positive effect on brain activity, enhancing mental fitness and stress resistance.
- Human Clinical Study Confirms Frutarom’s Neuravena® Enhances Mental Fitness and Stress Resistance
In-vitro and animal trials have demonstrated that Frutarom’s Neuravena® (EFLA® 955) wild green oat extract has a significant, positive effect on brain activity, enhancing mental fitness and stress resistance.
- Human Clinical Study Confirms Frutarom’s Neuravena® Enhances Mental Fitness and Stress Resistance
In-vitro and animal trials have demonstrated that Frutarom’s Neuravena® (EFLA® 955) wild green oat extract has a significant, positive effect on brain activity, enhancing mental fitness and stress resistance.
- According To New Study, Capros® Offers Different Antioxidant Properties Than Other Amla Extracts
According to a company study, the preparation of Capros® maintains the integrity of its antioxidant profile, allowing for more effective reduction of oxidative stress in the body when compared to other amla samples.
- According To New Study, Capros® Offers Different Antioxidant Properties Than Other Amla Extracts
According to a company study, the preparation of Capros® maintains the integrity of its antioxidant profile, allowing for more effective reduction of oxidative stress in the body when compared to other amla samples.
- New Study: Mirtogenol(TM) Lowers High Intraocular Hypertension
New research published in the July issue of Molecular Vision demonstrates that natural supplement Mirtogenol(TM), a combination of standardized bilberry extract Mirtoselect® and French maritime pine bark extract Pycnogenol®, lowers high intraocular pressure (IOP), which significantly reduces the likelihood of developing glaucoma.
- New Study: Mirtogenol(TM) Lowers High Intraocular Hypertension
New research published in the July issue of Molecular Vision demonstrates that natural supplement Mirtogenol(TM), a combination of standardized bilberry extract Mirtoselect® and French maritime pine bark extract Pycnogenol®, lowers high intraocular pressure (IOP), which significantly reduces the likelihood of developing glaucoma.
- New Study: Mirtogenol(TM) Lowers High Intraocular Hypertension
New research published in the July issue of Molecular Vision demonstrates that natural supplement Mirtogenol(TM), a combination of standardized bilberry extract Mirtoselect® and French maritime pine bark extract Pycnogenol®, lowers high intraocular pressure (IOP), which significantly reduces the likelihood of developing glaucoma.
- Study Proves Administration of PhosphoLean™ (N-Oleyl-Phosphatidylethanolamine and EGCG) Improves Diet Compliance, Insulin Resistance, Depressive Symptoms and Binge Eating Associated With Dieting
A study published by Dr. Mariangela Rondanelli, University of Pavia, Italy, in the July 2008 issue of the prestigious British Journal of Nutrition, proves that PhosphoLean(TM) NOPE + EGCG can significantly improve a person’s ability to stay on their stressful diet and successfully lose weight.
- Study Proves Administration of PhosphoLean™ (N-Oleyl-Phosphatidylethanolamine and EGCG) Improves Diet Compliance, Insulin Resistance, Depressive Symptoms and Binge Eating Associated With Dieting
A study published by Dr. Mariangela Rondanelli, University of Pavia, Italy, in the July 2008 issue of the prestigious British Journal of Nutrition, proves that PhosphoLean(TM) NOPE + EGCG can significantly improve a person’s ability to stay on their stressful diet and successfully lose weight.
- Study Proves Administration of PhosphoLean™ (N-Oleyl-Phosphatidylethanolamine and EGCG) Improves Diet Compliance, Insulin Resistance, Depressive Symptoms and Binge Eating Associated With Dieting
A study published by Dr. Mariangela Rondanelli, University of Pavia, Italy, in the July 2008 issue of the prestigious British Journal of Nutrition, proves that PhosphoLean(TM) NOPE + EGCG can significantly improve a person’s ability to stay on their stressful diet and successfully lose weight.
- Study Proves Administration of PhosphoLean™ (N-Oleyl-Phosphatidylethanolamine and EGCG) Improves Diet Compliance, Insulin Resistance, Depressive Symptoms and Binge Eating Associated With Dieting
A study published by Dr. Mariangela Rondanelli, University of Pavia, Italy, in the July 2008 issue of the prestigious British Journal of Nutrition, proves that PhosphoLean(TM) NOPE + EGCG can significantly improve a person’s ability to stay on their stressful diet and successfully lose weight.
- Study Proves Administration of PhosphoLean™ (N-Oleyl-Phosphatidylethanolamine and EGCG) Improves Diet Compliance, Insulin Resistance, Depressive Symptoms and Binge Eating Associated With Dieting
A study published by Dr. Mariangela Rondanelli, University of Pavia, Italy, in the July 2008 issue of the prestigious British Journal of Nutrition, proves that PhosphoLean(TM) NOPE + EGCG can significantly improve a person’s ability to stay on their stressful diet and successfully lose weight.
- Study Proves Administration of PhosphoLean™ (N-Oleyl-Phosphatidylethanolamine and EGCG) Improves Diet Compliance, Insulin Resistance, Depressive Symptoms and Binge Eating Associated With Dieting
A study published by Dr. Mariangela Rondanelli, University of Pavia, Italy, in the July 2008 issue of the prestigious British Journal of Nutrition, proves that PhosphoLean(TM) NOPE + EGCG can significantly improve a person’s ability to stay on their stressful diet and successfully lose weight.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Study Proves Beneficial Effects of Phosphatidylserine (PS) on Stress Management
A study published today in the Journal of the International Society of Sports Nutrition indicates that the consumption of a phosphatidylserine (PS) can help to effectively manage exercise induced stress and promote healthy free testosterone levels.
- Study Proves Beneficial Effects of Phosphatidylserine (PS) on Stress Management
A study published today in the Journal of the International Society of Sports Nutrition indicates that the consumption of a phosphatidylserine (PS) can help to effectively manage exercise induced stress and promote healthy free testosterone levels.
- Study Proves Beneficial Effects of Phosphatidylserine (PS) on Stress Management
A study published today in the Journal of the International Society of Sports Nutrition indicates that the consumption of a phosphatidylserine (PS) can help to effectively manage exercise induced stress and promote healthy free testosterone levels.
- Experts continue to cite Bifantis as promising probiotic treatment for Irritable Bowel Syndrome
Two new review articles that cover therapeutic approaches to irritable bowel syndrome (IBS) in the July issue of Nutrition in Clinical Practice, cite growing evidence that probiotics, and specifically Bifidobacterium infantis 35624 (Bifantis®), are effective in helping manage IBS.
- Experts continue to cite Bifantis as promising probiotic treatment for Irritable Bowel Syndrome
Two new review articles that cover therapeutic approaches to irritable bowel syndrome (IBS) in the July issue of Nutrition in Clinical Practice, cite growing evidence that probiotics, and specifically Bifidobacterium infantis 35624 (Bifantis®), are effective in helping manage IBS.
- Prestigious Confirmation of Low-Carb Diet Poised to Revitalize Weight Loss Nutraceutical Industry
A study published in the July 17th, 2008 edition of the New England Journal of Medicine1 showed clearly that a low-carb diet helped people lose more weight than a Mediterranean-style diet and the common low-fat diet. In addition, researchers discovered that a low-carb diet also helped improve healthy cholesterol ratios.
- Prestigious Confirmation of Low-Carb Diet Poised to Revitalize Weight Loss Nutraceutical Industry
A study published in the July 17th, 2008 edition of the New England Journal of Medicine1 showed clearly that a low-carb diet helped people lose more weight than a Mediterranean-style diet and the common low-fat diet. In addition, researchers discovered that a low-carb diet also helped improve healthy cholesterol ratios.
- Prestigious Confirmation of Low-Carb Diet Poised to Revitalize Weight Loss Nutraceutical Industry
A study published in the July 17th, 2008 edition of the New England Journal of Medicine1 showed clearly that a low-carb diet helped people lose more weight than a Mediterranean-style diet and the common low-fat diet. In addition, researchers discovered that a low-carb diet also helped improve healthy cholesterol ratios.
- New study suggests Carnipure(TM) supplementation improves bone mineral density
A new study released by the University of Connecticut, USA, suggests, that Carnipure(TM) tartrate supplementation can slow down bone loss and improve bone microstructural properties by decreasing bone turnover in aged ovariectomized rats.
- New study suggests Carnipure(TM) supplementation improves bone mineral density
A new study released by the University of Connecticut, USA, suggests, that Carnipure(TM) tartrate supplementation can slow down bone loss and improve bone microstructural properties by decreasing bone turnover in aged ovariectomized rats.
- New study suggests Carnipure(TM) supplementation improves bone mineral density
A new study released by the University of Connecticut, USA, suggests, that Carnipure(TM) tartrate supplementation can slow down bone loss and improve bone microstructural properties by decreasing bone turnover in aged ovariectomized rats.
- New Study shows that Gamma-Tocotrienol is the most Cardioprotective Tocotrienol
In a recent study published in the AJP-Heart and Circulatory Physiology, 2008, researchers at the University of Connecticut School of Medicine, used various isomers of tocotrienols, supplied by Carotech Inc, to study the effects and mechanism of tocotrienols’ cardioprotective function especially on their ability to improve post-ischemic ventricular function and reduce myocardial infarct size in rats. The results showed that gamma-tocotrienol was the most cardioprotective of all the isomers.
- New Study shows that Gamma-Tocotrienol is the most Cardioprotective Tocotrienol
In a recent study published in the AJP-Heart and Circulatory Physiology, 2008, researchers at the University of Connecticut School of Medicine, used various isomers of tocotrienols, supplied by Carotech Inc, to study the effects and mechanism of tocotrienols’ cardioprotective function especially on their ability to improve post-ischemic ventricular function and reduce myocardial infarct size in rats. The results showed that gamma-tocotrienol was the most cardioprotective of all the isomers.
- New Study shows that Gamma-Tocotrienol is the most Cardioprotective Tocotrienol
In a recent study published in the AJP-Heart and Circulatory Physiology, 2008, researchers at the University of Connecticut School of Medicine, used various isomers of tocotrienols, supplied by Carotech Inc, to study the effects and mechanism of tocotrienols’ cardioprotective function especially on their ability to improve post-ischemic ventricular function and reduce myocardial infarct size in rats. The results showed that gamma-tocotrienol was the most cardioprotective of all the isomers.
- 5-LOXIN® proven to reduce the symptoms of osteoarthritis in new human study published in Arthritis Research and Therapy
a new study published in Arthritis Research & Therapy examines the use of 5-LOXIN®, with researchers observing clinically and statistically significant improvements in pain scores and physical function scores in OA patients at doses of 100mg and 250mg daily.
- 5-LOXIN® proven to reduce the symptoms of osteoarthritis in new human study published in Arthritis Research and Therapy
a new study published in Arthritis Research & Therapy examines the use of 5-LOXIN®, with researchers observing clinically and statistically significant improvements in pain scores and physical function scores in OA patients at doses of 100mg and 250mg daily.
- 5-LOXIN® proven to reduce the symptoms of osteoarthritis in new human study published in Arthritis Research and Therapy
a new study published in Arthritis Research & Therapy examines the use of 5-LOXIN®, with researchers observing clinically and statistically significant improvements in pain scores and physical function scores in OA patients at doses of 100mg and 250mg daily.
- Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care.
- Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care.
- Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care.
- Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care.
- Pediatrics Journal Publishes Positive Safety Results of First Children's Trial Involving COLD-fX(R)
Pediatrics - the official journal of the American Academy of Pediatrics, has published safety results of a children's randomized, double-blind, placebo-controlled clinical trial involving COLD-fX®. The trial, designed to measure safety and tolerability, showed COLD-fX is safe for children.
- Pediatrics Journal Publishes Positive Safety Results of First Children's Trial Involving COLD-fX(R)
Pediatrics - the official journal of the American Academy of Pediatrics, has published safety results of a children's randomized, double-blind, placebo-controlled clinical trial involving COLD-fX®. The trial, designed to measure safety and tolerability, showed COLD-fX is safe for children.
- Pediatrics Journal Publishes Positive Safety Results of First Children's Trial Involving COLD-fX(R)
Pediatrics - the official journal of the American Academy of Pediatrics, has published safety results of a children's randomized, double-blind, placebo-controlled clinical trial involving COLD-fX®. The trial, designed to measure safety and tolerability, showed COLD-fX is safe for children.
- Enzymedica’s Free Radical Defenze(TM) Subject of First-place Scientific Poster Recognition at NPA Show
Enzymedica, Inc. has announced that a comparative analysis of its recently launched Free Radical Defenze(TM) antioxidant enzyme supplement received first-place honors in the Scientific Poster Session held Friday, July 18 at The Natural Products Association's Natural MarketPlace 2008 in Las Vegas, Nev.
- Enzymedica’s Free Radical Defenze(TM) Subject of First-place Scientific Poster Recognition at NPA Show
Enzymedica, Inc. has announced that a comparative analysis of its recently launched Free Radical Defenze(TM) antioxidant enzyme supplement received first-place honors in the Scientific Poster Session held Friday, July 18 at The Natural Products Association's Natural MarketPlace 2008 in Las Vegas, Nev.
- Enzymedica’s Free Radical Defenze(TM) Subject of First-place Scientific Poster Recognition at NPA Show
Enzymedica, Inc. has announced that a comparative analysis of its recently launched Free Radical Defenze(TM) antioxidant enzyme supplement received first-place honors in the Scientific Poster Session held Friday, July 18 at The Natural Products Association's Natural MarketPlace 2008 in Las Vegas, Nev.
- Enzymedica’s Free Radical Defenze(TM) Subject of First-place Scientific Poster Recognition at NPA Show
Enzymedica, Inc. has announced that a comparative analysis of its recently launched Free Radical Defenze(TM) antioxidant enzyme supplement received first-place honors in the Scientific Poster Session held Friday, July 18 at The Natural Products Association's Natural MarketPlace 2008 in Las Vegas, Nev.
- Pharmanex Study Correlates Skin Carotenoids to Overall Antioxidant Health
Scientists from Nu Skin Enterprises, Inc. (NUS) , presented results and consistency of findings from two large studies at the 15th International Symposium on Carotenoids in Okinawa, Japan, indicating that skin carotenoid levels measured with the Pharmanex(R) BioPhotonic Scanner correlate with, and are a good indication of, the body's overall antioxidant defense system.
- Pharmanex Study Correlates Skin Carotenoids to Overall Antioxidant Health
Scientists from Nu Skin Enterprises, Inc. (NUS) , presented results and consistency of findings from two large studies at the 15th International Symposium on Carotenoids in Okinawa, Japan, indicating that skin carotenoid levels measured with the Pharmanex(R) BioPhotonic Scanner correlate with, and are a good indication of, the body's overall antioxidant defense system.
- InterMed Discovery achieves Proof-of-Principle for IMD-026260
InterMed Discovery GmbH has announced that it has established proof-of-principle in a pre-clinical study for its optimized lead compound IMD-026260, an anti-cancer drug candidate.
- InterMed Discovery achieves Proof-of-Principle for IMD-026260
InterMed Discovery GmbH has announced that it has established proof-of-principle in a pre-clinical study for its optimized lead compound IMD-026260, an anti-cancer drug candidate.
- InterMed Discovery achieves Proof-of-Principle for IMD-026260
InterMed Discovery GmbH has announced that it has established proof-of-principle in a pre-clinical study for its optimized lead compound IMD-026260, an anti-cancer drug candidate.
- Potassium Increases May Lower Blood Pressure
A study in the July issue of the Journal of Clinical Hypertension has found that there is a potential link between increased levels of potassium and the lowering of blood pressure in adults.
- Potassium Increases May Lower Blood Pressure
A study in the July issue of the Journal of Clinical Hypertension has found that there is a potential link between increased levels of potassium and the lowering of blood pressure in adults.
- Potassium Increases May Lower Blood Pressure
A study in the July issue of the Journal of Clinical Hypertension has found that there is a potential link between increased levels of potassium and the lowering of blood pressure in adults.
- Potassium Increases May Lower Blood Pressure
A study in the July issue of the Journal of Clinical Hypertension has found that there is a potential link between increased levels of potassium and the lowering of blood pressure in adults.
- Potassium Increases May Lower Blood Pressure
A study in the July issue of the Journal of Clinical Hypertension has found that there is a potential link between increased levels of potassium and the lowering of blood pressure in adults.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
SAN DIEGO, CA, July 29, 2008, 2008 /PRNewswire-FirstCall via COMTEX/ -- Senomyx, Inc. (SNMX) , a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that it has initiated development activities for a new sucrose enhancer, S6973. Sucrose (otherwise known as common table sugar) is widely used in many food and beverage products. Taste tests have demonstrated that S6973 enables the reduction of up to 50% of the sucrose present in product prototypes while maintaining the sweet taste of natural sugar.
"Senomyx believes that S6973 has the potential to be used to enhance the sweet taste of sucrose in numerous food and beverage products," said Kent Snyder, President, Chief Executive Officer, and Chairman of the Board of Senomyx. "The discovery of S6973 is a major scientific accomplishment and represents a significant commercial opportunity for Senomyx. Flavor ingredients that enable a meaningful reduction in sucrose without compromising taste would provide consumers with new choices for products with lower calories and therefore improved nutritional profiles."
Unlike typical sugar alternatives, S6973 does not have a sweet taste of its own in taste tests with product prototypes. Instead, it is a unique flavor ingredient intended to amplify the sweet taste of the sugar present in a food or beverage. "Taste tests conducted by Senomyx have shown that S6973 enhanced the sweet taste of yogurt, cereal, and cookie prototypes, as well as powdered and other beverages," noted John Poyhonen, Senior Vice President, Chief Financial and Business Officer at the Company. "Senomyx is also planning to incorporate S6973 in additional product prototypes for evaluation by potential future collaborators. These prototypes are representative of product categories that utilize sucrose such as ice cream and other dairy products, sauces and toppings, and baked goods."
The development phase includes scale-up activities and safety studies to support regulatory filings for S6973 in the U.S. and elsewhere. Concurrent with its work with S6973, Senomyx is completing development activities with S2383, an enhancer of the high-intensity sweetener sucralose. S2383 enabled up to a 75% reduction of sucralose in simple product prototypes, yet maintained the same sweet intensity without any off-tastes. The Company anticipates that S2383 will receive GRAS (Generally Recognized As Safe) regulatory status in the U.S. by the end of 2008.
"We are excited to have achieved such important breakthroughs in our Sweet Enhancer Program," added Mark Zoller, Ph.D., Senomyx's Chief Scientific Officer and Executive Vice President of Discovery and Development. "Reducing sugar consumption is a priority for consumers who have dietary concerns, particularly those related to obesity and diabetes. The new sucrose and sucralose enhancers were discovered utilizing Senomyx's patented taste receptor technology, which we are now using to focus on the discovery of enhancers of fructose, another carbohydrate sweetener used in a wide range of consumer products."
About Senomyx, Inc. ( http://www.senomyx.com) Senomyx is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. Senomyx has entered into product discovery and development collaborations with seven of the world's foremost food, beverage, and ingredient supply companies: Ajinomoto Co., Inc., Cadbury plc, Campbell Soup Company, The Coca-Cola Company, Firmenich SA, Nestle SA, and Solae. NestlA(C) is currently marketing products that contain one of Senomyx's flavor ingredients. For more information, please visit http://www.senomyx.com.
Forward-Looking Statements Statements included in this press release that are not a description of fact are forward-looking statements, including, but not limited to, statements regarding the potential for using S6973 and S2383 as a sucrose enhancer in food and beverage products, whether Senomyx's current and potential future collaborators will use S6973 or S2383 in food products, our anticipation that S2383 will receive GRAS regulatory status by the end of 2008, the commercial potential of products containing our flavor ingredients, and whether we will enter into any new collaborations for S2383 or S6973 in the future. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans, projections or future financial, scientific or business objectives will be achieved. Our actual results may differ materially from any projected future results set forth in this release as a result of the risks and uncertainties inherent in our business including, without limitation: difficulties or delays in developing, testing, obtaining regulatory approval, producing, and marketing our flavor ingredients and related technologies; whether we are able to complete the satisfactory development of our novel flavor ingredients, including S2383 or S6973, when expected or at all; whether our development activities for novel flavor ingredients will demonstrate commercially acceptable safety profiles for our compounds; the ability of our licensees to manufacture S6973 and S2383 in commercial quantities at acceptable cost; whether we will be able to further extend or expand our existing collaborations or enter into additional collaborations in the future; our ability to collect royalties under our collaborations; the progress and timing of our scientific programs; changes in the laws or regulations of the United States and other countries that could adversely affect our and our collaborators' ability to develop and commercialize our products; whether any of our collaborations will result in the discovery and development of novel flavor ingredients, improve the nutritional profile of products incorporating them, or otherwise enhance our market position; our ability to protect our intellectual property and proprietary technology and to maintain and enforce our licensing arrangements with various third party licensors; our ability to define the scope and validity of patent protection for our products and technologies; competition from other companies and flavor manufacturers; and other risks detailed in our Securities and Exchange Commission filings, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof. |